Article
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice.
Breast cancer research and treatment - 1 Oct 2024
Bhave Manali A, Quintanilha Julia C F, Tukachinsky Hanna, Li Gerald, Scott Takara, Ross Jeffrey S, Pasquina Lincoln, Huang Richard S P, McArthur Heather, Levy Mia A, Graf Ryon P, Kalinsky Kevin
Abstract excerpt
BACKGROUND: The treatment landscape for HR(+)HER2(-) metastatic breast cancer (MBC) is evolving for patients with ESR1 mutations (mut) and PI3K/AKT pathway genomic alterations (GA). We sought to inform clinical utility for comprehensive genomic profiling (CGP) using tissue (TBx) and liquid biopsies (LBx) in HR(+)HER2(-) MBC. METHODS: Records from a de-identified breast cancer clinicogenomic database for patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.